Brenda C. Kakayi, BPharm, DPAM, MSc Epi has over 23 years of extensive experience in studies aimed at finding means of reducing mother to child transmission of HIV, best treatment options for HIV infected patients and other options in the prevention of HIV infection of HIV-negative individuals, TB prevention and treatment studies as well as vaccines for prevention of various infections.

She has been the CRS Pharmacist of Record (PoR) for close to 18 years and has worked on various NIH funded studies (ACTG, IMPAACT, MTN and HPTN) as the site PoR and Associate Pharmacist. She has experience in the pharmacy aspects involved in the conduct of Phase 1, 2, 3 and 4 trials and has demonstrated great leadership and guidance of the site’s pharmacy team in the conduct of these trials. She has also been involved in protocol development for non NIH-funded studies.

She is a 2023 IMPAACT Early Career Investigator Award recipient where she is studying “Insulin-like Growth Factor/Growth Hormone Levels and Stunting in HIV-Exposed Uninfected Children from the 1077BF/P1084s study”.